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Over the past few years, a number of anticancer drugs have been developed that specifically target kinases known to be oncogenic.
The leading drug in this area is imatinib mesylate, which targets ABL, KIT and PDGFR. It has been remarkably effective in the treatment
of chronic myeloid leukaemia, although resistance remains a significant problem. From the imatinib experience in this setting, we
present some principles of kinase inhibition that may have more general applicability in targeted anticancer therapy. It is clear that the
identification of appropriate targets (activated kinases) and monitoring levels of response (to recognise emerging resistance) are
essential to optimise clinical management.
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Kinases play a fundamental role in many cancers. Kinase
inhibition represents a promising new anticancer strategy. The
first kinase inhibitor to be developed for clinical use is imatinib
mesylate (Glivec, Novartis), which was designed for use in chronic
myeloid leukaemia (CML). In CML, the Philadelphia chromosome
(Ph) and variants result in a translocation that codes for the
chimaeric fusion protein, BCR-ABL, which is a constitutively
activated kinase. Imatinib inhibits the normal Abelson tyrosine
kinase (ABL) as well as BCR-ABL.
Imatinib inhibits other tyrosine kinases broadening the
potential therapeutic utility to a range of neoplastic disorders
(Buchdunger et al, 2002). The proto-oncogene C-KIT encodes the
KIT tyrosine kinase, which serves as a receptor for stem cell factor.
KIT is important in cell cycle regulation and critically important in
haematopoiesis. Two receptors for platelet-derived growth factor
(PDGF) are sensitive to imatinib. PDGF is involved in cell cycle
regulation, angiogenesis, and fibroblast proliferation (Claesson-
Welsh, 1994). Despite similarities in structure and function,
PDGFR a and b are encoded on different chromosomes and differ
in their affinity for individual isotypes of PDGF.
We review the current evidence regarding efficacy and safety of
imatinib in Philadelphia-positive (Phþ) haematological disorders
and in other disorders with evidence for imatinib sensitivity. We
also review the available data on imatinib resistance. We then




CML is a disorder of the haematopoietic stem cell consistently
associated with the BCR-ABL fusion gene. It is characterised by the
proliferation of the myeloid series, although lymphoid cells may
also arise from the malignant clone. Three phases of the disease are
recognised. In the chronic phase, there is indolent leukocytosis
with infiltration of the liver and spleen. In the accelerated phase,
there may also be acquisition of additional cytogenetic abnorm-
alities and an increase in the proportion of immature cells in the
blood or marrow. In blast crisis, which may be of lymphoid or
myeloid lineage, the clinical picture resembles de novo acute
leukaemia and carries a very poor prognosis.
Imatinib in newly diagnosed chronic phase
Prior to the introduction of imatinib, the accepted standard
therapy for newly diagnosed CML in the chronic phase was
interferon a and cytarabine. A recently published study (O’Brien
et al, 2003) randomised 1106 patients to interferon–cytarabine
combination therapy or imatinib at a dose of 400mg daily. With a
median follow-up of 19 months, no difference in the overall
survival could be demonstrated. However, crossover to imatinib
therapy occurred in 318 out of 553 patients (58%) in the
interferon–cytarabine group, largely due to intolerance of inter-
feron-related side effects. The rates of complete haematologic
response (CHR) (95 vs 56%), complete cytogenetic response (CCR:
76 vs 15%) and freedom from progression to accelerated phase or
blast crisis (97 vs 92%), all showed a statistically significant
improvement in the imatinib group.
Imatinib in chronic phase after interferon failure
Patients with prior exposure to interferon are mostly in the late
chronic phase (X12 months from diagnosis). Of 454 late chronic
phase patients started on imatinib at 400mg daily, 95% achieved
CHR and 41% CCR with freedom from progression in 89% at 18
months (Kantarjian et al, 2002). These results for imatinib therapy
are inferior to those observed in patients treated at diagnosis.
Two studies have looked at dose escalation in order to improve
the response rates in this group. With imatinib treatment at 800mg
daily in interferon-failed chronic phase (Cortes et al, 2003), CHR
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After 3 months, dose reduction due to toxicity had occurred in 42%,
with the most common grade III–IV toxicities being haematological.
Among patients started on imatinib 400mg daily, dose escalation was
an effective salvage therapy for refractoriness or relapse (Kantarjian
et al, 2003), but the overall results with this strategy were inferior to
those reported with treatment initiated at a higher dose.
Imatinib in accelerated phase
The accelerated phase of CML typically follows several years of
chronic phase and is associated with decreased response to therapy
and a shortened median survival of less than 1 year. A multicentre
study reporting on 181 patients treated with imatinib for
accelerated phase CML suggests lower response rates and
increased toxicity in comparison with the chronic phase (Talpaz
et al, 2002). Patients were initially commenced on imatinib at
400mg daily, but after efficacy and safety data became available,
subsequent patients were treated with 600mg daily. CHR was
achieved in 53% and sustained for at least 1 month in 34%. CCR
was achieved in 17%. With a median follow-up in excess of 10
months, there was a significant improvement in overall survival
and freedom from progression for the higher dose group. Grade
III–IV haematological toxicity occurred in 58% and severe
nonhaematological toxicity was uncommon (o5%).
Imatinib in blast crisis and Phþ acute lymphoblastic
leukaemia (ALL)
In blast crisis of CML and in de novo Phþ ALL, BCR-ABL retains
sensitivity to imatinib, but additional genetic abnormalities
conferring drug resistance are common. In patients with relapsed
or refractory Phþ ALL or lymphoid blast crisis (Ottmann et al,
2002) and in myeloid blast crisis (Sawyers et al, 2002), CHR was
achieved in around 20%. Despite good haematological response, in
most cases relapse occurred early with a median survival of only
20–30 weeks. Relapse is commonly associated with emergence of
mutations in the BCR-ABL kinase (Gorre et al, 2001; von Bubnoff
et al, 2002).
Other myeloid disorders
A clinical phenotype closely mimicking CML has been described in
a patient carrying a BCR-PDGFRA fusion gene (Baxter et al, 2002).
Response to imatinib was not tested. This, and potentially other
fusion kinases, may account for the rare cases of otherwise typical
CML, which lack BCR-ABL.
The cytogenetic abnormality t(5;12) has been described in a rare
myeloproliferative disorder with leukocytosis and eosinophilia.
Splenomegaly and skin infiltration may be present. The transloca-
tion is usually associated with a fusion of TEL (a regulatory gene
that may be translocated in acute leukaemia) and PDGFRB
(Apperley et al, 2002). Four patients with myeloproliferative
disorder and confirmed PDGFRB fusion were treated with imatinib
400mg daily. All achieved CHR after 4 weeks and cytogenetic
remission after 9 months.
Idiopathic hypereosinophilic syndrome is characterised by
persistent peripheral blood eosinophilia with evidence of end-
organ damage (usually cardiac or sinopulmonary infiltration or
neuropathy) without an identifiable cause. In a series of 16 patients
with idiopathic hypereosinophilic syndrome, a novel fusion of
PDGFRA and FIP1L1 has been reported (Cools et al, 2003). Nine
patients were found to have this fusion gene, with eight of these
having a cryptic deletion of chromosome 4. Five of these nine
patients and a further five patients without PDGFRA-FIP1L1 fusion
received imatinib treatment. The doses of imatinib ranged from
100 to 400mg daily. CHR of at least 3 months duration was
achieved in all but two patients, neither of whom carried the fusion
gene. Efficacy at lower doses than in CML is supported by in vitro
data, indicating that the IC50 (drug concentration required to
inhibit proliferation by 50%) for imatinib of PDGFRa-FIP1L1 is
approximately 2-log lower than for BCR-ABL.
Imatinib-responsive idiopathic hypereosinophilic syndrome
without an identified molecular abnormality has also been
reported elsewhere (Ault et al, 2002; Gleich et al, 2002). Gleich
et al report on five patients treated with imatinib. Four patients
achieved CHR. The starting dose was 100mg daily and main-
tenance doses were as low as 200mg per week. These results imply
that another cryptic rearrangement involving PDGFR (or another
imatinib-sensitive kinase) may be present in some patients.
Systemic mastocytosis is a rare myeloproliferative disorder with
an increase in mast cells in the marrow and evidence of visceral
and cutaneous infiltration. A syndrome related to histamine
release may also occur. Imatinib inhibition of KIT phosphorylation
in mast cell lines correlates with the inhibition of cellular
proliferation (Zermati et al, 2003), suggesting that the cells are
critically dependent on KIT activity. In systemic mastocytosis, the
most common activating mutation in C-KIT D816V, occurs in the
catalytic region of the enzyme, and also prevents binding of
imatinib. Most cases of mastocytosis are therefore resistant to
imatinib. However, patients with mutations in the juxtamembrane
region of the KIT molecule may retain in vitro sensitivity (Zermati
et al, 2003) and durable clinical responses to imatinib in doses of
400mg daily or less have been demonstrated (Pardanani et al,
2002).
The importance of PDGF in the development of fibrosis and of
KIT in haematopoiesis makes idiopathic myelofibrosis an appeal-
ing target for imatinib therapy. However, the results of treatment
have been mixed. The results of a phase 2 trial of imatinib in 23
patients with idiopathic myelofibrosis (Tefferi et al, 2002) were
disappointing. Partial responses were observed in some patients,
but no clinically significant benefit was obtained and haematolo-
gical toxicity was greater than that observed in the chronic phase
of CML, despite use of the standard starting dose of 400mg daily.
On the other hand, Cortes et al. (2002) observed improvement in
cell counts or reduction in the spleen size in over 50% of 18
patients treated with the same dose of imatinib.
A study using C-KIT antisense oligonucleotides in vitro suggests
that normal erythropoiesis is significantly dependent on KIT
function (Ratajczak et al, 1992). In polycythaemia rubra vera,
although the expression of KIT is normal, an increased sensitivity
of the receptor to its ligand, stem cell factor, has been observed
(Dai et al, 1994). These observations provide a rationale for the
trials of imatinib in this myeloproliferative disorder. Reports in the
small numbers of patients report reduced phlebotomy requirement
with imatinib treatment (Cortes et al, 2002; Silver, 2002; Jones and
Dickinson, 2003).
In acute myeloid leukaemia (AML), KIT is expressed in at least
two-thirds of cases, although the number with C-KIT mutations is
much smaller. In a series of de novo childhood AML (Zwaan et al,
2002), C-KIT was found to be mutated in 6.4% with the imatinib-
resistant D816V mutation accounting for approximately half of
these. An in vitro study using leukaemic cells from 12 patients
found an overall poor response to imatinib at pharmacological
doses (Scappini et al, 2001), although there was significant
heterogeneity between leukaemia samples. This most likely reflects
that in most cases of AML, KIT is not critically involved in
sustaining abnormal proliferation, unlike BCR-ABL, which is
pathogenetic in CML. Similarly, among 17 KIT-positive patients
with relapsed or refractory AML treated with imatinib mono-
therapy, there were no haematological remissions (Cortes et al,
2002). Despite these negative findings, imatinib-responsive AML
has been reported, with some cases achieving CHR (Fischer et al,
2002; Kindler et al, 2003). The clarification of the molecular
pathways involved in such cases may help identify a subset of AML
that will benefit from imatinib treatment.
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Constitutive activation of KIT is almost universal in gastrointest-
inal stromal tumours (GIST), and often associated with gain-of-
function mutations in C-KIT. A study of material from GISTs of 48
patients revealed mutations in C-KIT in 92%, with the majority
located in exon 11, which encodes the juxtamembrane region
involved in activating dimerisation (Rubin et al, 2001).
Interestingly, a recent report found that among the small
percentage of C-KIT wild-type GISTs, approximately one-third had
mutations in the PDGFRA gene with evidence of abnormal
activation of its tyrosine kinase (Heinrich et al, 2003). This
overlap in disease phenotypes associated with mutations in
different tyrosine kinases is mirrored in the myeloproliferative
disorders with eosinophilia, and highlights the case for accurate
genetic diagnosis.
Impressive activity of imatinib monotherapy has been demon-
strated in a single study of 147 patients with unresectable or
metastatic GIST (Demetri et al, 2002), despite refractoriness to
conventional chemoradiotherapy. Partial response (reduction in
tumour volume X50%) was achieved in 54%, with only 14%
showing evidence of disease progression at a median follow-up of
288 days. The median time to measurable response was 13 weeks.
The median time to disease progression was not reached within
288 days. Within the study there was a randomisation of imatinib
dose (400 vs 600mg daily). There was no significant difference in
the response or toxicity between the two groups. However, nine
patients with disease progression on the lower dose were crossed
over to the higher dose and three achieved improvement in disease
control.
Other solid tumours
The expression of KIT or PDGFRb has been observed in a number
of solid tumours, including small cell lung cancer, thyroid cancer,
ovarian and breast cancers, prostate cancer, seminoma, glioblas-
toma, and dermatofibrosarcoma protruberans. For some of these
tumours, there is in vitro evidence of inhibition by imatinib
(Buchdunger et al, 2002; Heinrich et al, 2002a). In contrast to CML,
the inhibition of a single signalling pathway will not usually be
sufficient to overcome the proliferative advantage of the tumour.
Clinical efficacy data are awaited.
Diagnosis and monitoring
Chronic myeloid leukaemia is one of very few diseases for which
there is a universally identifiable, single genetic abnormality that
provides an ideal target for therapy. In CML, the demonstration of
BCR-ABL confirms suitability for therapy, as well as providing a
target for disease monitoring. Diagnostic and monitoring strate-
gies for CML and other imatinib-sensitive disorders are presented
below and summarised in Table 1.
Quantitative monitoring of BCR-ABL mRNA by reverse
transcriptase PCR is used to follow response. Progressive
reduction in BCR-ABL levels may be observed over a long period,
sometimes in excess of 1 year before reaching a plateau. Increases
in BCR-ABL levels are observed with the development of resistance
to therapy (Hughes and Branford 2003). A single institution study
of 120 late chronic phase (interferon resistant or intolerant)
patients (Merx et al, 2002) monitored response to imatinib (400mg
daily) with peripheral blood quantitative real-time polymerase
chain reaction (qPCR) for BCR-ABL mRNA. There was a strong
correlation between bone marrow karyotype (% Phþ metaphases)
and the BCR-ABL/ABL ratio by qPCR. In addition, the level of
BCR-ABL at 2 months was predictive of cytogenetic response at 6
months. At least in the short term, attainment of a major
cytogenetic response (p35% Phþ metaphases) is associated with
a survival advantage. It seems likely that the kinetics of qPCR
response will become a useful prognostic marker to identify high-
risk individuals who may not respond well to imatinib mono-
therapy.
In other imatinib-responsive disorders, despite greater genetic
heterogeneity, molecular diagnosis and monitoring should be the
goal. At least in the case of myeloproliferative disorders (e.g.
PDGFRA-FIP1L1 fusion, Cools et al), there is evidence that this will
be possible. Where the molecular abnormality has not been
identified, there may still be a role for other biological markers of
imatinib responsiveness. For example, the inhibition of abnormal
phosphorylation of target molecules should potentially be
measurable in any imatinib-sensitive disorder, although in the
case of solid tumours availability of tumour tissue may limit
monitoring options.
The functional monitoring of a subset of 64 GIST patients of
Demetri et al. (2002) was undertaken with
18fluoro-deoxy-glucose
positron emission tomography (PET) in addition to standard
radiological imaging. All patients who achieved a response had a
reduction in PET activity from baseline. PET responses occurred
early (even within 24h). Loss of response was associated with
increased PET activity in all cases. Furthermore, a later report
(van den Abbeele et al, 2002) showed that PET response within the
first month of imatinib therapy was a strong predictor of
progression-free survival over the subsequent 16 months of
follow-up.
Preliminary data on the genetic prediction of imatinib response
in GIST were presented by Heinrich et al. (2002b). They undertook
mutation detection in C-KIT in 121 cases of unresectable GIST and
correlated these findings with the clinical course of the disease.
The presence of mutations in exon 11 predicted both significantly
higher rates of response to imatinib (72 vs 32%) and longer time to
treatment failure. In contrast, in an earlier study, in patients
treated without imatinib, exon 11 mutation was found to be an
independent adverse prognostic factor in multivariate analysis
(Singer et al, 2002). In the future, the detection of specific C-KIT
mutations may be used to guide imatinib dosing or combination
therapy in GIST patients.
TOXICITY
Typically, in CML at the commencement of imatinib therapy,
haematopoiesis is almost exclusively derived from the BCR-ABL
Table 1 Diagnosis and monitoring of imatinib-sensitive disorders
Disorder Genetics Diagnosis Monitoring
CML BCR-ABL fusion Karyotype, PCR Karyotype quantitative PCR BCR-
ABL mutation screening
Hyper-eosinophilic syndromes Various involving PDGFRA and PDGFRB Karyotype, PCR Karyotype quantitative PCR
mutation screening
Systemic mastocytosis C-KIT activating mutation KIT immunohistochemistry, C-KIT
mutation detection
Gastrointestinal stromal tumours C-KIT activating mutation KIT immunohistochemistry, C-KIT
mutation detection
PET
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cytopenia until there is a recovery of the suppressed residual
normal haematopoiesis. Clinical trials in the different phases of
CML indicate an increase in haematological toxicity with more
advanced disease. Doses beyond 600mg daily appeared to be
associated with increased toxicity. Even with higher rates of
cytopenia, dose-limiting and fatal toxicities were relatively
uncommon.
In contrast, in GIST there was little evidence of an effect on
normal haematopoiesis, as grade III–IV thrombocytopenia did not
occur and grade IV neutropenia was reported in only 5%. The rates
of nonhaematological toxicity appear similar in all trials for both
CML and GIST and the drug is generally well-tolerated.
While the short-term side effects of imatinib are generally well-
documented, the potential longer-term consequences of kinase
blockade remain uncertain. Extrapolation from observations in
animal models is difficult as inhibition of kinase function in a
mature animal will clearly not produce the range of developmental
anomalies seen in germline knockout studies. In addition, some
tyrosine kinase-dependent defects may become significant only in
stressed conditions, such as inflammation and tissue repair (Van
Etten, 1999). However, in knockout mice there is evidence of
osteoporosis and defective osteoblast maturation (Li et al, 2000);
defects in spermatogenesis (Guerif et al, 2002); abnormal lymphoid
proliferation and differentiation, and abnormal melanin metabo-
lism (Van Etten, 1999; Hou et al, 2000). This latter observation is
significant in view of clinical reports of hypopigmentation in
patients receiving imatinib (Saikia et al, 2002; Hasan et al, 2003).
Continuing surveillance for delayed effects of kinase blockade will
be important.
IMATINIB RESISTANCE
Resistance has been studied extensively in CML, where acquired
imatinib resistance is defined as a loss of established haematologic
or cytogenetic response to imatinib, as opposed to primary
resistance, in which no response is achieved. In CML, acquired
resistance is usually associated with restoration of BCR-ABL kinase
activity (Gorre et al, 2001). Data on resistance in other imatinib-
responsive disorders are limited at present, but it is likely that the
patterns emerging in CML will be applicable to other disease
models.
What is the mechanism of drug resistance?
Three broad mechanisms may result in the restoration of kinase
activity: (1) decreased intracellular levels of imatinib; (2) increased
expression of the kinase; or (3) intrinsic changes in the kinase that
affect its drug interaction or kinase activity.
MDR1 overexpression causing drug efflux (Mahon et al, 2003)
has been shown to cause imatinib resistance in Phþ cell lines in
vitro. The binding of imatinib to a1 acid glycoprotein has been
reported to reduce the availability of the drug in vivo, with a
demonstration of resistance in vitro (Gambacorti-Passerini et al,
2002). Low levels of imatinib have been reported in cerebrospinal
fluid (Petzer et al, 2002), suggesting that this may be a ‘sanctuary’
site for residual disease.
Increased levels of BCR-ABL kinase, related to genomic
amplification of the BCR-ABL gene, or increased levels of
expression has been observed. Importantly, an in vitro model
demonstrated that exposure to low levels of imatinib promoted the
development of genomic amplification, whereas effective drug
levels did not (Le Coutre et al, 2000).
Finally, mutations in BCR-ABL may impair imatinib binding.
This mechanism has perhaps been most widely studied and
appears to be the most common mechanism of resistance in
clinical practice (Gorre et al, 2001; Branford et al, 2002; Hochhaus
et al, 2002; Shah et al, 2002; Branford et al, 2003).
To study the frequency of point mutations in BCR-ABL, CML
patients were screened with sequencing of the ABL kinase domain
(Branford et al, 2003). All had received at least 6 months of
imatinib therapy and were studied regardless of response.
Mutations were found in 27 out of 144 patients and were
associated with acquired resistance in 89% and with shortened
survival.
In contrast, point mutations in BCR-ABL are not commonly
seen in primary refractory patients. In a separate study (Branford
et al, 2002), only one out of 10 CML patients with primary
resistance to imatinib therapy had a BCR-ABL mutation, suggest-
ing that a different mechanism is responsible in this setting.
Are all mutations equally important?
There are limited data regarding the clinical significance of each
individual mutation, but overall, their emergence in imatinib
resistance indicates an association with poor prognosis. In CML
patients treated with imatinib, emergence of mutations at amino-
acid positions 250–255, which form the adenosine triphosphate-
binding loop (P-loop), carried an especially poor prognosis with 12
of 13 (92%) dying at a median of 18 weeks from the detection of
the mutation (Branford et al, 2003). Among 14 patients with non-
P-loop mutations only three (21%) died, with a similar follow-up
from the time of detection.
The in vitro significance of individual mutations can be assessed
more readily. Methods include inhibition of substrate phosphor-
ylation and inhibition of cell culture. Reported IC50 values of
clinically detected mutations are presented in Table 2. These values
are derived from in vitro cell lines engineered to express a specific
mutant BCR-ABL gene. For comparison, the mean plasma trough
concentration of imatinib 400mg daily is 1.46mM (Corbin et al,
2003). CML mutant clones with an IC50 close to or below this value
should be more likely to respond well to dose escalation.
Gambacorti-Passerini et al (2003) divide the BCR-ABL muta-
tions into groups according to the functional regions of the
molecule where they occur. In the first group, mutations such as
T315I are in the imatinib-binding site. Other mutations involve the
P-loop (e.g. E255K) and presumed regulatory regions of the
enzyme (e.g. M351T) remote from the imatinib-binding site.
Heinrich et al (2002c) suggest a similar classification of the KIT-
activating mechanisms of GIST. The major group of abnormalities
involves regulatory portions of KIT, so the imatinib-binding
region is unaffected. Hopefully, a better understanding of the
C-KIT mutations present at diagnosis will help optimise both patient
selection and tailoring of therapy. As may occur in the accelerated
phase of CML, they also present evidence for the acquisition of
additional karyotypic abnormalities in more advanced GIST. Such
abnormalities may be predicted to augment the KIT-dependent
transformation or confer KIT-independent malignant potential.
However, the precise molecular mechanisms underlying acquired
imatinib resistance in GIST are yet to be elucidated.
Unlike GIST, in systemic mastocytosis activation of KIT is
typically associated with point mutations in the enzymatic region
of the molecule. The most common of these mutations (D816V)
shows no response to imatinib in vitro (Zermati et al, 2003), while
the proliferation of normal mast cells containing wild-type C-KIT
was significantly inhibited. It is thought that the D816V mutation
interferes with the interaction of imatinib and its KIT binding site.
This finding is analogous to T315I in CML, which disrupts the
noncovalent interactions essential for the binding of imatinib to
the BCR-ABL kinase.
In idiopathic hypereosinophilic syndrome (Cools et al, 2003),
there is another parallel to the CML experience in that acquired
drug resistance was observed in one patient with emergence of a
point mutation in PDGFRA-FIP1L1, again showing structural
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mutation was tested, it was found to show a 3-log increase from
wild type.
When do resistant mutations arise?
It seems that at least in some cases of CML, mutations conferring
resistance are in fact present in a small number of leukaemic cells
prior to treatment and are positively selected by imatinib therapy.
Interpretation of studies investigating this problem is complicated
by the use of different methodologies with varying sensitivity.
However, four patients with primary cytogenetic refractoriness
had BCR-ABL mutations identified using direct cDNA sequencing
(Roche-Lestienne et al, 2002). Retrospective analysis of pretreat-
ment specimens using allele-specific oligonucleotide PCR (ASO-
PCR) was able to demonstrate low levels of mutant cDNA in all
four cases, indicating clonal selection. Similarly, von Bubnoff et al
(2002) noted an increase in the proportion of mutant mRNA with
sequential monitoring of relapsing patients.
Further evidence in support of this hypothesis comes from the
finding that the duration of disease prior to commencement of
imatinib is a significant predictor of resistance-conferring muta-
tions (Branford et al, 2003). In a group of 144 patients classified
according to disease phase at commencement of imatinib, no early
chronic phase patients had detectable mutations, while 22% of late
chronic phase patients carried mutations. Furthermore, patients
who started imatinib therapy more than 4 years from diagnosis
had a higher incidence of mutations (41%) than those treated
within 4 years (9%).
Can imatinib cure CML?
Despite excellent initial responses to imatinib, it is unclear whether
long-term control of chronic phase CML will be achieved with
monotherapy. Although imatinib has been shown to promote
apoptosis, there are in vitro data indicating that primitive Phþ
stem cells not undergoing mitosis remain viable following
exposure to the drug (Graham et al, 2002). Such cells could
provide a therapy-resistant pool responsible for late relapse.
In advanced phases of CML, there may be secondary oncogenic
abnormalities (e.g. P53 mutations) that change the biologic
behaviour of the CML clone. Emergence of BCR-ABL-independent
pathways supporting proliferation or resistance to apoptosis will
inevitably diminish the efficacy of imatinib monotherapy.
Can imatinib combination therapy overcome resistance?
There is significant in vitro evidence indicating synergism of
combinations of imatinib with conventional cytotoxics and newer
biological therapies. Inhibition of heat shock protein, hsp90, and
histone deacetylase results in degradation of BCR-ABL and
induction of apoptosis in imatinib-resistant CML cell lines and
shows synergism with imatinib (Schad et al, 2002; Nimmanapalli
et al, 2003). Targeting alternative pathways of signal transduction,
for example with farnesyl transferase inhibitors, also shows
promise in imatinib-resistant CML cell lines (Hoover et al, 2002;
Topaly et al, 2002).
Following on from in vitro studies, there are a number of
preliminary reports of Phase I/II trials in imatinib-resistant CML
using imatinib with gemtuzumab anti-CD33 monoclonal antibody
(Sallah et al, 2002), imatinib with farnesyl transferase inhibitor,
lonafarnib (Cortes et al, 2002a), and imatinib with cytotoxics
(Mauro et al, 2002; Fruehauf et al, 2003; Maloisel et al, 2003).
Overall, the main toxicity of combination therapy was increased
myelosuppression, although this was generally well-tolerated.
In newly diagnosed chronic phase CML, trials combining
imatinib and interferon a (Baccarani et al, 2002; Hochhaus et al,
2003) or imatinib and cytarabine (Cornelissen et al, 2002;
Gardembas et al, 2002) are in progress. It seems likely that
combination approaches will lead to a lower incidence of
resistance, but this remains to be tested formally.
IMPLICATIONS FOR CANCER THERAPY
The use of imatinib in CML has been a striking success and has
spurred an increase in research to develop molecular-based
therapies in a range of conditions. What has this experience taught
us about the use of kinase inhibitors in cancer therapy? Firstly,
it is worth noting that some observations may be unique to CML.
Table 2 IC50 values for BCR-ABL mutations
IC50 (lM imatinib)
BCR-ABL type Corbin (2003) Azam (2003) Hochhaus (2002) Shah (2002) Von Bubnoff (2002)
Wild-type ABL 0.025
Wild-type BCR-ABL 0.5 0.6 0.6 40.1o0.5
M244V 1.6 3.1
M244I 1.4
G250E 4.5 420 410
Q252H 2.6 2.9
Y253H 417.7 17.7 3.7 410
Y253F 5.0 1.8
E255V 417.7 45 410
E255K 7.5 12.1 45 410 410
F311L 0.7 1.3
T315I 417.7 420 410 410
T315S 3.8
F317L 1.3 2.3 7.5
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blockade of a single pathway may not represent effective mono-
therapy. Thus, the remarkable activity of imatinib as monotherapy
may not be observed in most cancer settings. However, some key
observations are likely to have broader implications:
(1) Experience in CML, and more recently in GIST and
myeloproliferative disorders, indicates the importance of
identifying a molecular target that can be inhibited and that
also provides a critical transforming signal for tumour cells.
This needs to be distinguished from tumours that simply
express a potential target kinase, but are not critically
dependent upon the kinase pathway.
(2) Blockade of a kinase that provides a significant growth signal
in malignant cells may nullify the proliferative advantage of a
tumour, but may not induce apoptosis. In CML, the amount of
leukaemia present in the blood and marrow falls rapidly over
the first few months of imatinib therapy, but residual
leukaemia is usually still detectable with longer follow-up.
This is the predicted pattern of response for an agent that
blocks proliferation but does not induce cell death in
leukaemic stem cells. The stem cell population may remain
relatively intact because they are generally quiescent and not
dependent on overactive kinase activity for survival. Combi-
nation therapy with a second agent capable of inducing
apoptosis, or inducing cell division in quiescent cells may
prove highly effective.
(3) Molecular diagnostics are playing an increasingly important
role in the assessment of malignancy. At least in myelopro-
liferative disorders, and perhaps also in GIST, there is
potential for patients with a similar clinicopathological
presentation to harbour differing genetic abnormalities
involving related tyrosine kinase pathways. This emphasises
the need for accurate genetic diagnosis wherever possible.
Molecular diagnosis will also improve our capacity to monitor
disease response.
(4) Ideally, patients should be selected on the basis of in vitro
testing to establish that their tumour is effectively targeted.
Assessment of a kinase-dependent malignancy could include a
screen for kinase mutations or polymorphisms that prevent
binding of the kinase inhibitor and/or determination of the
IC50. This would enable both appropriate use of the kinase
inhibitor and identification of patients who will benefit from
dose escalation or combination therapies. Optimal dosing
should be based on extensive pharmacokinetic studies with
verification of optimal target blockade. Where tumour tissue is
available, PCR-based detection of drug-resistant mutations
should be a component of monitoring, so that necessary
changes to therapy may be initiated early.
(5) The development of acquired resistance is a significant
concern in the CML setting, with over 20 possible mutations
in BCR-ABL capable of leading to resistance. This illustrates
the potential limitation of monotherapy using a highly specific
kinase inhibitor that is likely to be relevant for many cancers.
A similar observation of resistance due to kinase point
mutation has been reported in a patient receiving imatinib
for idiopathic hypereosinophilic syndrome.
(6) In CML, imatinib has its highest response rate when used soon
after diagnosis, while resistant kinase mutations increase in
frequency with disease duration and advanced phase of
disease. Early and effective kinase inhibition may also be
crucial to optimise treatment outcomes in other kinase-
dependent malignancies.
(7) Most importantly, careful elucidation of the cause of resistance
in CML has led to detailed understanding of how the kinase
works and how it interacts with inhibitors. This understanding
has contributed to the development of new BCR-ABL
inhibitors designed to be less susceptible to inactivation by a
single amino acid substitution as well as providing an
additional rationale for combination therapy. Similar detailed
analysis of the cause of resistance with other kinase inhibitors
is likely to be equally valuable.
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